Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs

W. H. Hsiang, J. B. Jiang, Leroy-Fong Liu

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Treatment of SV40-infected monkey cells with amonafide (benzisoquinolinedione), an intercalative antitumor drug, resulted in rapid accumulation of linearized intracellular SV40 DNA molecules that were protein linked. Studies using purified mammalian DNA topoisomerase II have shown that amonafide and its structural analogs interfere with the breakage-rejoining reaction of the enzyme by stabilizing a reversible enzyme-DNA 'cleavable complex'. Denaturation of the cleavable complex with sodium dodecyl sulfate resulted in DNA cleavage and the covalent association of topoisomerase II polypeptides with the cleaved DNA. Unwinding measurements indicate that amonafide is a DNA intercalator. These results suggest that amonafide and its structural analogs (e.g., mitonafide) represent a new class of intercalative topoisomerase II-active antitumor drugs. Different from other topoisomerase II-active antitumor drugs, amonafide and mitonafide induce specific DNA cleavage at a single major site on pBR322 DNA. The strong site specificity of amonafide may allow detailed characterization of the intercalator-stabilized, topoisomerase II-DNA cleavable complex.

Original languageEnglish
Pages (from-to)371-376
Number of pages6
JournalMolecular Pharmacology
Volume36
Issue number3
Publication statusPublished - 1989
Externally publishedYes

Fingerprint

amonafide
Type II DNA Topoisomerase
DNA Cleavage
Antineoplastic Agents
DNA
Intercalating Agents
Enzymes
Sodium Dodecyl Sulfate
Haplorhini

ASJC Scopus subject areas

  • Pharmacology

Cite this

Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs. / Hsiang, W. H.; Jiang, J. B.; Liu, Leroy-Fong.

In: Molecular Pharmacology, Vol. 36, No. 3, 1989, p. 371-376.

Research output: Contribution to journalArticle

@article{ba142ac6f6dc4e148f6978099eea59f2,
title = "Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs",
abstract = "Treatment of SV40-infected monkey cells with amonafide (benzisoquinolinedione), an intercalative antitumor drug, resulted in rapid accumulation of linearized intracellular SV40 DNA molecules that were protein linked. Studies using purified mammalian DNA topoisomerase II have shown that amonafide and its structural analogs interfere with the breakage-rejoining reaction of the enzyme by stabilizing a reversible enzyme-DNA 'cleavable complex'. Denaturation of the cleavable complex with sodium dodecyl sulfate resulted in DNA cleavage and the covalent association of topoisomerase II polypeptides with the cleaved DNA. Unwinding measurements indicate that amonafide is a DNA intercalator. These results suggest that amonafide and its structural analogs (e.g., mitonafide) represent a new class of intercalative topoisomerase II-active antitumor drugs. Different from other topoisomerase II-active antitumor drugs, amonafide and mitonafide induce specific DNA cleavage at a single major site on pBR322 DNA. The strong site specificity of amonafide may allow detailed characterization of the intercalator-stabilized, topoisomerase II-DNA cleavable complex.",
author = "Hsiang, {W. H.} and Jiang, {J. B.} and Leroy-Fong Liu",
year = "1989",
language = "English",
volume = "36",
pages = "371--376",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs

AU - Hsiang, W. H.

AU - Jiang, J. B.

AU - Liu, Leroy-Fong

PY - 1989

Y1 - 1989

N2 - Treatment of SV40-infected monkey cells with amonafide (benzisoquinolinedione), an intercalative antitumor drug, resulted in rapid accumulation of linearized intracellular SV40 DNA molecules that were protein linked. Studies using purified mammalian DNA topoisomerase II have shown that amonafide and its structural analogs interfere with the breakage-rejoining reaction of the enzyme by stabilizing a reversible enzyme-DNA 'cleavable complex'. Denaturation of the cleavable complex with sodium dodecyl sulfate resulted in DNA cleavage and the covalent association of topoisomerase II polypeptides with the cleaved DNA. Unwinding measurements indicate that amonafide is a DNA intercalator. These results suggest that amonafide and its structural analogs (e.g., mitonafide) represent a new class of intercalative topoisomerase II-active antitumor drugs. Different from other topoisomerase II-active antitumor drugs, amonafide and mitonafide induce specific DNA cleavage at a single major site on pBR322 DNA. The strong site specificity of amonafide may allow detailed characterization of the intercalator-stabilized, topoisomerase II-DNA cleavable complex.

AB - Treatment of SV40-infected monkey cells with amonafide (benzisoquinolinedione), an intercalative antitumor drug, resulted in rapid accumulation of linearized intracellular SV40 DNA molecules that were protein linked. Studies using purified mammalian DNA topoisomerase II have shown that amonafide and its structural analogs interfere with the breakage-rejoining reaction of the enzyme by stabilizing a reversible enzyme-DNA 'cleavable complex'. Denaturation of the cleavable complex with sodium dodecyl sulfate resulted in DNA cleavage and the covalent association of topoisomerase II polypeptides with the cleaved DNA. Unwinding measurements indicate that amonafide is a DNA intercalator. These results suggest that amonafide and its structural analogs (e.g., mitonafide) represent a new class of intercalative topoisomerase II-active antitumor drugs. Different from other topoisomerase II-active antitumor drugs, amonafide and mitonafide induce specific DNA cleavage at a single major site on pBR322 DNA. The strong site specificity of amonafide may allow detailed characterization of the intercalator-stabilized, topoisomerase II-DNA cleavable complex.

UR - http://www.scopus.com/inward/record.url?scp=0024469320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024469320&partnerID=8YFLogxK

M3 - Article

C2 - 2550774

AN - SCOPUS:0024469320

VL - 36

SP - 371

EP - 376

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 3

ER -